Delcath Systems, Inc. (DCTH) Starts Presentation at LD Micro Main Event
Delcath Systems (OTC: DCTH) is a specialty pharmaceutical and medical device company focused on oncology. The company’s proprietary product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS), is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. The company's principal focus is on the treatment of primary and metastatic liver cancers. The company has commenced a global phase 2 clinical trial in Europe to investigate Melphalan/HDS system for primary liver cancer and is initiating plans to evaluate intrahepatic cholangiocarcinoma. For more information, visit the company’s website at…







